Saud Sadiq

Summary

Publications

  1. ncbi Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making
    Violaine K Harris
    Multiple Sclerosis Research Center of New York, New York, New York 10019, USA
    Mol Diagn Ther 13:225-44. 2009
  2. ncbi Intrathecal methotrexate treatment in multiple sclerosis
    Saud A Sadiq
    Multiple Sclerosis Research Center of New York, 4th Floor, New York, NY 10019, USA
    J Neurol 257:1806-11. 2010
  3. ncbi Inhibition of SLPI ameliorates disease activity in experimental autoimmune encephalomyelitis
    André Michael Müller
    Multiple Sclerosis Research Center of New York, 521 W 57th Street, 4th Floor, New York, NY 10019, USA
    BMC Neurosci 13:30. 2012
  4. ncbi Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS
    Saud A Sadiq
    Division of Hematology Oncology, Department of Medicine, St Luke s Roosevelt Hospital, New York, NY, USA
    Mult Scler 14:272-3. 2008
  5. ncbi JCV detection in multiple sclerosis patients treated with natalizumab
    Saud A Sadiq
    Multiple Sclerosis Research Center of New York, 521 West 57th Street, 4th Floor, New York, NY 10019, USA
    J Neurol 257:954-8. 2010
  6. ncbi Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis
    Soheli A Chowdhury
    Multiple Sclerosis Research Center of New York, 521 W 57th Street, New York, NY 10019, USA
    Arch Neurol 65:232-5. 2008

Research Grants

  1. HSP60 ABNORMALITIES IN SCHIZOPHRENIA
    Saud Sadiq; Fiscal Year: 2001

Collaborators

  • André Michael Müller
  • Violaine K Harris
  • Soheli A Chowdhury
  • Esther Jun
  • Hana Conlon
  • Jerry Lin

Detail Information

Publications6

  1. ncbi Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making
    Violaine K Harris
    Multiple Sclerosis Research Center of New York, New York, New York 10019, USA
    Mol Diagn Ther 13:225-44. 2009
    ..The discovery of new biomarkers relies on applying advances in proteomics along with microarray gene and antigen analysis and will hopefully result in the establishment of specific biomarkers for MS...
  2. ncbi Intrathecal methotrexate treatment in multiple sclerosis
    Saud A Sadiq
    Multiple Sclerosis Research Center of New York, 4th Floor, New York, NY 10019, USA
    J Neurol 257:1806-11. 2010
    ..ITMTX may have a beneficial role in progressive forms of MS and is well tolerated with no serious adverse events...
  3. ncbi Inhibition of SLPI ameliorates disease activity in experimental autoimmune encephalomyelitis
    André Michael Müller
    Multiple Sclerosis Research Center of New York, 521 W 57th Street, 4th Floor, New York, NY 10019, USA
    BMC Neurosci 13:30. 2012
    ..The secretory leukocyte protease inhibitor (SLPI) exerts wide ranging effects on inflammatory pathways and is upregulated in EAE but the biological role of SLPI in EAE, an animal model of multiple sclerosis is unknown..
  4. ncbi Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS
    Saud A Sadiq
    Division of Hematology Oncology, Department of Medicine, St Luke s Roosevelt Hospital, New York, NY, USA
    Mult Scler 14:272-3. 2008
    ..This underscores the need for only using mitoxantrone in severe treatment-unresponsive cases of MS...
  5. ncbi JCV detection in multiple sclerosis patients treated with natalizumab
    Saud A Sadiq
    Multiple Sclerosis Research Center of New York, 521 West 57th Street, 4th Floor, New York, NY 10019, USA
    J Neurol 257:954-8. 2010
    ..Screening for JCV in CSF in natalizumab-treated patients could help identify those at heightened risk for developing PML and discontinuing treatment in these patients may abort development of the clinical illness...
  6. ncbi Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis
    Soheli A Chowdhury
    Multiple Sclerosis Research Center of New York, 521 W 57th Street, New York, NY 10019, USA
    Arch Neurol 65:232-5. 2008
    ..Despite recent advances in therapy that have improved the overall disease course in multiple sclerosis (MS), the prognosis at the outset remains unpredictable...

Research Grants3

  1. HSP60 ABNORMALITIES IN SCHIZOPHRENIA
    Saud Sadiq; Fiscal Year: 2001
    ..Molecular studies will involve genomic and cDNA cloning of hsp60 from peripheral and brain tissue. Epitope mapping will be done by ELISA using overlapping peptides spanning the entire normal human hsp60 sequence. ..